Last Price$4.3(4.0%)
Market Cap$211.4B
(42.1%)
Peers median - 18.9%
(270.5%)
Peers median - 2.8%
0.1%
Peers median - 5.2%
(1,274.8%)
Peers median - (13.8%)
Competing with SLN
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$211.4B | 5.6 | $0.0 99.8% overvalued | (83.5%) | £16.2M | (£43.9M) | (42.1%) | (270.5%) | 44.8% | (1,274.8%) | 0.1% | |
$402.0B | 6.7 | $60.0 32.9% overvalued | (29.6%) | DKK 290.4B | DKK 70.0B | 25.0% | 24.1% | 84.7% | 35.5% | 71.6% | |
$125.5B | 5.7 | $195.0 59.6% overvalued | 14.0% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$74.0B | 6.5 | $1,013.8 48.0% undervalued | (29.5%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 86.7% | 25.0% | 5.7% | |
$38.1B | 5.8 | $109.1 82.5% overvalued | 59.5% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$31.3B | 5.2 | $93.6 61.6% overvalued | 62.3% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$27.1B | 6.3 | $165.8 48.6% undervalued | 24.9% | €3,040.1M | €985.3M | (54.1%) | 32.4% | 84.3% | (41.4%) | 1.3% | |
$14.8B | 5.6 | $46.7 33.6% overvalued | 17.6% | $4,241.2M | $235.2M | 14.8% | 5.5% | 92.3% | (12.7%) | 1.3% | |
$14.6B | 5.9 | $0.5 97.4% overvalued | 327.0% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$14.0B | 7.7 | $427.2 37.8% undervalued | 35.5% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$1,846.9M | 5.4 | $2,805.1 1,137.3% undervalued | 39.9% | $3,316.8M | ($1,009.2M) | 50.5% | (30.4%) | 83.1% | (38.4%) | 32.1% |
Compare SLN Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Silence Therapeutics plcSLN
10,233.8x
45.7%
(6.7%)
(170.5%)
Median Peer Set
3.5x
18.9%
(47.6%)
0.4%
Alnylam Pharmaceuticals, Inc.ALNY
13.3x
23.0%
(38.6%)
(12.4%)
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
0.1x
73.7%
(56.5%)
(35.9%)
BioNTech SEBNTX
3.1x
(77.4%)
(89.7%)
24.4%
Incyte CorporationINCY
3.0x
14.8%
(94.0%)
0.8%
Novo Nordisk A/SNVO
10.2x
24.9%
142.8%
34.8%
Regeneron Pharmaceuticals, Inc.REGN
4.1x
8.3%
10.4%
31.1%
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
United Therapeutics CorporationUTHR
3.8x
23.6%
25.7%
41.5%
Vertex Pharmaceuticals IncorporatedVRTX
11.0x
11.7%
N/A
(4.9%)
Compare SLN Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Silence Therapeutics plc (SLN) revenue growth compare to peers and the industry?
Silence Therapeutics plc (SLN) revenue growth is (42.1%), compared to the peers' median of 18.9%.
2. How does Silence Therapeutics plc (SLN) Free Cash Flow (FCF) margin compare to peers and the industry?
Silence Therapeutics plc (SLN) FCF margin is (270.5%), compared to the peers' median of 2.8%.
3. How does Silence Therapeutics plc (SLN) Total Debt to Equity ratio compare to peers and the industry?
Silence Therapeutics plc (SLN) Total Debt to Equity ratio is 0.1%, compared to the peers' median of 5.2%.
4. How does Silence Therapeutics plc (SLN) ROIC (Return on Invested Capital) compare to peers and the industry?
Silence Therapeutics plc (SLN) ROIC is (1,274.8%), compared to the peers' median of (13.8%).